Mukesh Sharma Paudel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mukesh Sharma Paudel has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Amrendra Mandal
Internal Medicine, Interfaith Medical Center, Brooklyn, USA
4 shared publications Baikuntha Chaulagai
Internal Medicine, Interfaith Medical Center, Brooklyn, USA
4 shared publications- Vijay Gayam
Department of Medicine, Interfaith Medical Center, Brooklyn, USA
4 shared publications Khushboo Goel
Department of Periodontology, Institute of Medicine, Kathmandu, Nepal
3 shared publicationsParitosh Kafle
Internal Medicine, Interfaith Medical Center, Brooklyn, USA
3 shared publications- Abel Botelho Quaresma
Health Sciences Postgraduate Program, IBD outpatient clinics, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil; Universidade do Oeste de Santa Catarina, UNOESC, Joaçaba, Brazil
2 shared publications
Latest Publications
- Open Access
- 22 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8)
Impact of Socioeconomic Determinants and Lifestyle Factors on the Severity of Periodontal Diseases in Adults
Introduction: The association between periodontal diseases with socioeconomic and lifestyle factors is multifaceted. The disparities are also well recognized. The present study aims to assess the impact of socioeconomic determinants, oral hygiene practices, and lifestyle factors on the severity of probing depths and bleeding on probing in Nepalese adults. Methods: A total of 374 adults were included in the analysis. Independent associations of socio-demographic, oral hygiene, and lifestyle factors on dependent variables of bleeding on probing and severe periodontitis defined as ≥6 mm probing depth were determined using the chi-squared test/Fisher's exact test with multivariate and ordinal logistic regression analysis. Results: The mean age of participants was 42.40±12.51 years. The occurrence of periodontal disease was found to be 62.3%. Multivariate analysis revealed that poor oral hygiene had a markedly increased likelihood of bleeding on probing. Bivariate analysis of probing depths revealed age, bleeding on probing, and oral hygiene status, along with lifestyle factors such as smoking and smokeless tobacco, to be statistically significant with severe probing depths. There was also an elevated risk of severe probing depths among individuals of lower socioeconomic status and their determinants. The results, however, were not statistically significant. Ordinal regression analysis revealed age with an estimate of 1.286 (p=0.001), bleeding on probing with an estimate of 0.811 (p=0.030), and additionally lifestyle factors such as current smokers with an estimate of 0.991 (p=0.002) to have a risk of severe probing depths among reported individuals. Conclusion: Poor oral hygiene and unfavorable lifestyle factors such as smoking were strongly associated with bleeding on probing and severe probing depths. This indicates that while deep pockets are prevalent, their association with lower socioeconomic status and other lifestyle factors did not show significant changes.
- 22 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8)
Open AccessImpact of Socioeconomic Determinants and Lifestyle Factors on the Severity of Periodontal Diseases in Adults
Introduction: The association between periodontal diseases with socioeconomic and lifestyle factors is multifaceted. The disparities are also well recognized. The present study aims to assess the impact of socioeconomic determinants, oral hygiene practices, and lifestyle factors on the severity of probing depths and bleeding on probing in Nepalese adults. Methods: A total of 374 adults were included in the analysis. Independent associations of socio-demographic, oral hygiene, and lifestyle factors on dependent variables of bleeding on probing and severe periodontitis defined as ≥6 mm probing depth were determined using the chi-squared test/Fisher's exact test with multivariate and ordinal logistic regression analysis. Results: The mean age of participants was 42.40±12.51 years. The occurrence of periodontal disease was found to be 62.3%. Multivariate analysis revealed that poor oral hygiene had a markedly increased likelihood of bleeding on probing. Bivariate analysis of probing depths revealed age, bleeding on probing, and oral hygiene status, along with lifestyle factors such as smoking and smokeless tobacco, to be statistically significant with severe probing depths. There was also an elevated risk of severe probing depths among individuals of lower socioeconomic status and their determinants. The results, however, were not statistically significant. Ordinal regression analysis revealed age with an estimate of 1.286 (p=0.001), bleeding on probing with an estimate of 0.811 (p=0.030), and additionally lifestyle factors such as current smokers with an estimate of 0.991 (p=0.002) to have a risk of severe probing depths among reported individuals. Conclusion: Poor oral hygiene and unfavorable lifestyle factors such as smoking were strongly associated with bleeding on probing and severe probing depths. This indicates that while deep pockets are prevalent, their association with lower socioeconomic status and other lifestyle factors did not show significant changes.
- Top Cited PapersOpen Access
- 30 April 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 458-466
Global evolution of inflammatory bowel disease across epidemiologic stages
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.
- 30 April 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 458-466
Top Cited PapersOpen AccessGlobal evolution of inflammatory bowel disease across epidemiologic stages
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.
- Open Access
- 15 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77467
Peroral Endoscopic Myotomy (POEM) for Achalasia Cardia: A Report of Two Cases
Achalasia cardia is a motility disorder of the esophagus characterized by a lack of esophageal peristalsis and failure of lower esophageal sphincter opening during swallowing. Symptomatic patients present with a long history of difficulty swallowing, along with chest pain and vomiting.
- 15 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77467
Open AccessPeroral Endoscopic Myotomy (POEM) for Achalasia Cardia: A Report of Two Cases
Achalasia cardia is a motility disorder of the esophagus characterized by a lack of esophageal peristalsis and failure of lower esophageal sphincter opening during swallowing. Symptomatic patients present with a long history of difficulty swallowing, along with chest pain and vomiting.
- Open Access
- 1 January 2025
- Published by Georg Thieme Verlag KG in Journal of Gastrointestinal Infections
- Vol. 15 (01/02) , 7-14
Microbial Profile and Antibiotic Susceptibility of Organisms in Bile Cultures from Patients Undergoing Endoscopic Retrograde Cholangiography: A Cross-Sectional Study from a Tertiary-Care Center in Nepal
Acute cholangitis, a potentially life-threatening biliary infection, frequently arises from biliary obstruction. Prompt diagnosis and appropriate antimicrobial therapy are critical to preventing sepsis and reducing mortality. Empirical antibiotic selection requires an understanding of local microbial profiles and resistance patterns. This study aims to describe the microbial profile and antibiotic resistance patterns in bile cultures obtained from patients undergoing endoscopic retrograde cholangiography (ERC) at a tertiary-care teaching hospital in Kathmandu, Nepal, and assess if there is a difference in prevalence rates between these groups. This cross-sectional study was conducted at a tertiary-care teaching hospital in Nepal between November 2023 and April 2024. A total of 88 patients (44 with acute cholangitis and 44 without) undergoing ERC were included. Bile samples were aseptically collected, cultured, and analyzed for microbial identification and antibiotic susceptibility. Statistical analysis was performed with a two-tailed two-sample proportion z-test to compare bile culture positivity and microbial patterns between groups. Of the 88 patients, 74 (84%) had positive bile cultures, with a significantly higher prevalence in the cholangitis group (93%) compared with those without cholangitis (75%, p = 0.041). Gram-negative organisms predominated, with Escherichia coli (38%), Citrobacter (30%), and Klebsiella (19%) being the most common. Pseudomonas species were isolated exclusively in the cholangitis group. Antibiotic resistance rates were high, including multidrug resistance among Pseudomonas and Enterobacter isolates. This study highlights the high prevalence of gram-negative pathogens in ERC patients with cholangitis, emphasizing targeted empiric therapy and antimicrobial stewardship.
- 1 January 2025
- Published by Georg Thieme Verlag KG in Journal of Gastrointestinal Infections
- Vol. 15 (01/02) , 7-14
Open AccessMicrobial Profile and Antibiotic Susceptibility of Organisms in Bile Cultures from Patients Undergoing Endoscopic Retrograde Cholangiography: A Cross-Sectional Study from a Tertiary-Care Center in Nepal
Acute cholangitis, a potentially life-threatening biliary infection, frequently arises from biliary obstruction. Prompt diagnosis and appropriate antimicrobial therapy are critical to preventing sepsis and reducing mortality. Empirical antibiotic selection requires an understanding of local microbial profiles and resistance patterns. This study aims to describe the microbial profile and antibiotic resistance patterns in bile cultures obtained from patients undergoing endoscopic retrograde cholangiography (ERC) at a tertiary-care teaching hospital in Kathmandu, Nepal, and assess if there is a difference in prevalence rates between these groups. This cross-sectional study was conducted at a tertiary-care teaching hospital in Nepal between November 2023 and April 2024. A total of 88 patients (44 with acute cholangitis and 44 without) undergoing ERC were included. Bile samples were aseptically collected, cultured, and analyzed for microbial identification and antibiotic susceptibility. Statistical analysis was performed with a two-tailed two-sample proportion z-test to compare bile culture positivity and microbial patterns between groups. Of the 88 patients, 74 (84%) had positive bile cultures, with a significantly higher prevalence in the cholangitis group (93%) compared with those without cholangitis (75%, p = 0.041). Gram-negative organisms predominated, with Escherichia coli (38%), Citrobacter (30%), and Klebsiella (19%) being the most common. Pseudomonas species were isolated exclusively in the cholangitis group. Antibiotic resistance rates were high, including multidrug resistance among Pseudomonas and Enterobacter isolates. This study highlights the high prevalence of gram-negative pathogens in ERC patients with cholangitis, emphasizing targeted empiric therapy and antimicrobial stewardship.
- Open Access
- 27 July 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (8) , e01447
Extraosseous Ewing Sarcoma With Upper Gastrointestinal Bleeding
Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is a type of malignancy that usually appears as a tumor in the bone. However, in a few patients with ES/PNET, it can occur outside of the bone. Although extraosseous ES/PNET can appear in various parts of the body, involvement of small bowel is rare. If it does, it can present with vague abdominal pain and gastrointestinal bleeding. This case report presents a 28-year-old gentleman with extraosseous ES/PNET in the duodenum who experienced gastrointestinal bleeding as a presenting symptom.
- 27 July 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (8) , e01447
Open AccessExtraosseous Ewing Sarcoma With Upper Gastrointestinal Bleeding
Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is a type of malignancy that usually appears as a tumor in the bone. However, in a few patients with ES/PNET, it can occur outside of the bone. Although extraosseous ES/PNET can appear in various parts of the body, involvement of small bowel is rare. If it does, it can present with vague abdominal pain and gastrointestinal bleeding. This case report presents a 28-year-old gentleman with extraosseous ES/PNET in the duodenum who experienced gastrointestinal bleeding as a presenting symptom.
- Open Access
- 23 January 2024
- Published by Springer Nature in Research Square
The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages
During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD.
- 23 January 2024
- Published by Springer Nature in Research Square
Open AccessThe Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages
During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD.
- Open Access
- 2 August 2021
- Published by Springer Nature in Cureus
- Vol. 13 (8)
Endoscopic Detection and Management of Esophagogastric Varices
Gastrointestinal (GI) varices are abnormally dilated submucosal veins in the digestive tract caused due to portal hypertension. Esophagus and stomach are common locations of varices induced by portal hypertension. Their presence correlates with the severity of the liver disease. Endoscopic variceal band ligation is one of the preferred methods for bleeding and nonbleeding large varices to decrease bleeding risk. Tissue adhesives such as N-butyl-2-cyanoacrylate have been used for gastric variceal obturation. This descriptive study was conducted in the Department of Gastroenterology, National Academy of Medical Sciences, Kathmandu, Nepal, from March 2014 to January 2020. The endoscopic detection of esophageal and gastric varices was observed. Endoscopic variceal ligation (EVL) was done for esophageal varices and injection of N-butyl 2-cyanoacrylate for gastric varices. Esopahageal varices were detected in 1266 patients (8%) and gastric varices were in 36 patients (0.2%) among 15,657 patients undergoing upper gastrointestinal (UGI) endoscopy. Nine hundred seven (71.6%) were male. Large esophageal varices were endoscopically detected in 54.8% patients, small varices in 31.4% and both (large and small varices) in 13.4%. EVL was done in 30.7% and EVL with cyanoacrylate glue injection in 35 patients (2.7%). Esophageal and gastric varices are seen commonly in patients with chronic liver disease. This study was conducted to describe the different types of GI varices in patients undergoing UGI endoscopy. Variceal band ligation for esophageal varices and glue injection for gastric varices are viable options of management.
- 2 August 2021
- Published by Springer Nature in Cureus
- Vol. 13 (8)
Open AccessEndoscopic Detection and Management of Esophagogastric Varices
Gastrointestinal (GI) varices are abnormally dilated submucosal veins in the digestive tract caused due to portal hypertension. Esophagus and stomach are common locations of varices induced by portal hypertension. Their presence correlates with the severity of the liver disease. Endoscopic variceal band ligation is one of the preferred methods for bleeding and nonbleeding large varices to decrease bleeding risk. Tissue adhesives such as N-butyl-2-cyanoacrylate have been used for gastric variceal obturation. This descriptive study was conducted in the Department of Gastroenterology, National Academy of Medical Sciences, Kathmandu, Nepal, from March 2014 to January 2020. The endoscopic detection of esophageal and gastric varices was observed. Endoscopic variceal ligation (EVL) was done for esophageal varices and injection of N-butyl 2-cyanoacrylate for gastric varices. Esopahageal varices were detected in 1266 patients (8%) and gastric varices were in 36 patients (0.2%) among 15,657 patients undergoing upper gastrointestinal (UGI) endoscopy. Nine hundred seven (71.6%) were male. Large esophageal varices were endoscopically detected in 54.8% patients, small varices in 31.4% and both (large and small varices) in 13.4%. EVL was done in 30.7% and EVL with cyanoacrylate glue injection in 35 patients (2.7%). Esophageal and gastric varices are seen commonly in patients with chronic liver disease. This study was conducted to describe the different types of GI varices in patients undergoing UGI endoscopy. Variceal band ligation for esophageal varices and glue injection for gastric varices are viable options of management.
- Open Access
- 28 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
Epidemiology of Inflammatory Bowel Diseases in Nepal
Inflammatory bowel diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). These are diseases of the gastrointestinal tract without a clear etiology but have strong relationships with underlying factors like genetic susceptibility, environmental factors, and intestinal bacteria. In the east, inflammatory bowel diseases predominantly affect the younger population and have an almost equal gender distribution. With urbanization and the adoption of the western lifestyle, the incidence and prevalence of IBD are increasing in Asia. In this study, we describe the epidemiology of IBD in Nepal. This was an observational study conducted in nine endoscopy centers within Nepal. Two years of data of colonoscopies in these centers were collected retrospectively. IBD was diagnosed by endoscopic examination. The incidence of IBD was calculated as the number of patients with IBD per 1000 colonoscopies per year. The demographic profiles of the patients were also collected. A total of 7526 colonoscopies were done in nine centers within the two years study period. IBD was seen in 479 patients (6.3%). The incidence of UC was 23.7 per 1000 colonoscopies per year and the incidence of CD was 1.6 per 1000 colonoscopies per year. UC (87%) was more common than CD (13%). Both UC and CD were mostly seen in the 30 to 40 years age group. In patients with UC, the rectum was the most commonly affected site. IBD in Nepal affects young males in their thirties. Younger age of affliction with a chronic disease and lack of awareness regarding the symptoms and diagnostic modalities of IBD may result in a delayed diagnosis. The target population must be made aware of the presenting symptoms of IBD and a need for colonoscopic examination for diagnosis. There is also a need for creating a national IBD registry for Nepal.
- 28 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
Open AccessEpidemiology of Inflammatory Bowel Diseases in Nepal
Inflammatory bowel diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). These are diseases of the gastrointestinal tract without a clear etiology but have strong relationships with underlying factors like genetic susceptibility, environmental factors, and intestinal bacteria. In the east, inflammatory bowel diseases predominantly affect the younger population and have an almost equal gender distribution. With urbanization and the adoption of the western lifestyle, the incidence and prevalence of IBD are increasing in Asia. In this study, we describe the epidemiology of IBD in Nepal. This was an observational study conducted in nine endoscopy centers within Nepal. Two years of data of colonoscopies in these centers were collected retrospectively. IBD was diagnosed by endoscopic examination. The incidence of IBD was calculated as the number of patients with IBD per 1000 colonoscopies per year. The demographic profiles of the patients were also collected. A total of 7526 colonoscopies were done in nine centers within the two years study period. IBD was seen in 479 patients (6.3%). The incidence of UC was 23.7 per 1000 colonoscopies per year and the incidence of CD was 1.6 per 1000 colonoscopies per year. UC (87%) was more common than CD (13%). Both UC and CD were mostly seen in the 30 to 40 years age group. In patients with UC, the rectum was the most commonly affected site. IBD in Nepal affects young males in their thirties. Younger age of affliction with a chronic disease and lack of awareness regarding the symptoms and diagnostic modalities of IBD may result in a delayed diagnosis. The target population must be made aware of the presenting symptoms of IBD and a need for colonoscopic examination for diagnosis. There is also a need for creating a national IBD registry for Nepal.
- Open Access
- 28 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
The prevalence of non-alcoholic fatty liver disease (NAFLD) is 60% in patients with type 2 diabetes mellitus (T2DM). NAFLD can lead to non-alcoholic steatohepatitis (NASH), both of which are the leading causes of cirrhosis. This study was undertaken to evaluate whether empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces liver fat content in these patients after therapy. After enrolling patients of T2DM with NAFLD, they were administered empagliflozin 10 mg once daily orally for six months without modifying existing oral hypoglycemic agents (OHA) if any. All demographic data were collected, and anthropometric measurements, as well as laboratory investigations, were performed, and controlled attenuation parameter (CAP) and liver stiffness (LS) were measured using FibroScan® (Echosens, Paris, France) at baseline, and six months of therapy. The adverse effects related to therapy were also taken into account. There was a significant decrease in mean CAP value from 282.07 ± 47.29 dB/m to 263.07 ± 49.93 dB/m and LS from 5.89 ± 4.23 kPa to 5.04 ± 1.49 kPa along with a significant decrease in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) among the patients. Compared to the baseline, there was a significant reduction in post-treatment weight, body mass index (BMI), and blood pressure (BP). The most commonly observed adverse effects of the therapy were urinary tract infection (UTI) (17.8%), nasopharyngitis (11.9%), and hypoglycemia (10.71%). A reduction in hepatic fat content was seen in our prospective study cohort after six months of empagliflozin therapy. Empagliflozin also led to beneficial effects such as weight loss and reduction in transaminases and GGT. Given the absence of significant side effects of the therapy, empagliflozin could be used as an effective treatment modality for T2DM patients with NAFLD, which are two conditions commonly seen in combination.
- 28 July 2021
- Published by Springer Nature in Cureus
- Vol. 13 (7)
Open AccessThe Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
The prevalence of non-alcoholic fatty liver disease (NAFLD) is 60% in patients with type 2 diabetes mellitus (T2DM). NAFLD can lead to non-alcoholic steatohepatitis (NASH), both of which are the leading causes of cirrhosis. This study was undertaken to evaluate whether empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces liver fat content in these patients after therapy. After enrolling patients of T2DM with NAFLD, they were administered empagliflozin 10 mg once daily orally for six months without modifying existing oral hypoglycemic agents (OHA) if any. All demographic data were collected, and anthropometric measurements, as well as laboratory investigations, were performed, and controlled attenuation parameter (CAP) and liver stiffness (LS) were measured using FibroScan® (Echosens, Paris, France) at baseline, and six months of therapy. The adverse effects related to therapy were also taken into account. There was a significant decrease in mean CAP value from 282.07 ± 47.29 dB/m to 263.07 ± 49.93 dB/m and LS from 5.89 ± 4.23 kPa to 5.04 ± 1.49 kPa along with a significant decrease in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) among the patients. Compared to the baseline, there was a significant reduction in post-treatment weight, body mass index (BMI), and blood pressure (BP). The most commonly observed adverse effects of the therapy were urinary tract infection (UTI) (17.8%), nasopharyngitis (11.9%), and hypoglycemia (10.71%). A reduction in hepatic fat content was seen in our prospective study cohort after six months of empagliflozin therapy. Empagliflozin also led to beneficial effects such as weight loss and reduction in transaminases and GGT. Given the absence of significant side effects of the therapy, empagliflozin could be used as an effective treatment modality for T2DM patients with NAFLD, which are two conditions commonly seen in combination.